ETEPLIRSEN
| Brand name | EXONDYS 51 |
|---|---|
| Active ingredient | ETEPLIRSEN |
| Strength | 500MG/10ML (50MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | September 2016 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9506058 | March 2034 | use U-1919 |
| 10364431 | March 2034 | use U-1918 |
| 10337003 | March 2034 | use U-1918 |
| RE47769 | February 2029 | product |
| RE48468 | October 2028 | use U-2097 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.